Assembly Biosciences Appoints New CEO, CMO, CFO

Ticker: ASMB · Form: 8-K · Filed: 2024-03-15T00:00:00.000Z

Sentiment: neutral

Topics: management-change, executive-appointment

TL;DR

New CEO, CMO, and CFO in at Assembly Bio. Big changes ahead?

AI Summary

Assembly Biosciences, Inc. announced on March 12, 2024, a series of significant leadership changes. Dr. Henry "Hank" Alfred, Jr. has been appointed as the new Chief Executive Officer and a member of the Board of Directors. Additionally, Dr. David J. E. Duffield has joined as Chief Medical Officer, and Ms. Jennifer L. Jones has been appointed as Chief Financial Officer. These appointments are effective immediately.

Why It Matters

The appointment of new executive leadership, including a CEO, CMO, and CFO, often signals a strategic shift or a new direction for the company, potentially impacting its future development and financial performance.

Risk Assessment

Risk Level: medium — Changes in key executive positions can introduce uncertainty regarding the company's future strategy and operational execution.

Key Players & Entities

FAQ

Who has been appointed as the new CEO of Assembly Biosciences, Inc.?

Dr. Henry "Hank" Alfred, Jr. has been appointed as the new Chief Executive Officer.

When were these executive appointments effective?

The appointments were effective as of March 12, 2024.

What other key executive positions were filled?

Dr. David J. E. Duffield was appointed as Chief Medical Officer, and Ms. Jennifer L. Jones was appointed as Chief Financial Officer.

Is the new CEO also joining the Board of Directors?

Yes, Dr. Henry "Hank" Alfred, Jr. has been appointed as a member of the Board of Directors.

What is the principal executive office address for Assembly Biosciences, Inc.?

The address is Two Tower Place, 7th Floor, South San Francisco, California 94080.

From the Filing

0000950170-24-032162.txt : 20240315 0000950170-24-032162.hdr.sgml : 20240315 20240315160513 ACCESSION NUMBER: 0000950170-24-032162 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240312 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240315 DATE AS OF CHANGE: 20240315 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASSEMBLY BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001426800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35005 FILM NUMBER: 24754666 BUSINESS ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (833) 409-4583 MAIL ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: VENTRUS BIOSCIENCES INC DATE OF NAME CHANGE: 20080211 8-K 1 asmb-20240312.htm 8-K 8-K 0001426800 false 0001426800 2024-03-12 2024-03-12     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)       Two Tower Place , 7th Floor , South San Francisco , California 94080 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: (833) 509-4583 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001   ASMB   The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐         Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) On March 13, 2024, the Board appointed Robert D. Cook II, a designee of Gilead Sciences, Inc. ("Gilead"), to serve on the Board. Mr. Cook is Gilead's Vice President, Risk Governance and Audit and was designated for appointment to the Board pursuant to the previously announced Investor Rights Agreement entered into between the Company and Gilead on October 15, 2023. Mr.

View on Read The Filing